Assessing Bronchiectasis Progression in Low-dose Screening for Lung Cancer
Assuming similar progression rates, ~136 out of 2182 participants are expected to progress on follow-up screening. This study sheds light on bronchiectasis progression and its significant predictors in a low-dose CT screening program. We recommend reporting bronchiectasis as participants who have smoked are at increased risk, and continued assessment over the entire period of participation in the low-dose CT screening program would allow for the identification of possible causes, early warning, and even early treatment.
Authors
- Claudia I. Henschke (ORCID: https://orcid.org/0000-0002-6085-5305)
- Mark L. Metersky (ORCID: https://orcid.org/0000-0003-1968-1400)
- Natthaya Triphuridet (ORCID: https://orcid.org/0000-0002-8998-9104)
- Rowena Yip (ORCID: https://orcid.org/0000-0002-6208-2780)
- Qiang Cai (ORCID: https://orcid.org/0000-0003-3055-666X)
- Yeqing Zhu (ORCID: https://orcid.org/0000-0003-0593-5553)
- David F. Yankelevitz
Institutions
- Chulabhorn Hospital (TH)
- UConn Health (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of Thoracic Imaging
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1097/rti.0000000000000812
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00